key: cord-0804476-x4jimgg3
authors: Giacomelli, Andrea; Pagani, Gabriele; Conti, Federico; Bassoli, Cinzia; Galli, Massimo
title: Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy
date: 2021-01-13
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.12.026
sha: 1bd9a0de216a4b7a822ba47f92fc76383f76dc3f
doc_id: 804476
cord_uid: x4jimgg3

nan

We read with interest the paper by Crespo et al., who suggested that mass severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) testing offers a unique opportunity to screen for viral hepatitis, particularly hepatitis C virus (HCV) infection [1] .

As the COVID-19 pandemic has overwhelmed entire national healthcare systems and severely strained their ability to manage patients with chronic diseases, such as those with chronic viral hepatitis [2] , we agree that access to screening programmes and subsequent linkage to care would possibly turn the challenges of the pandemic in new opportunities.

Mass serological SARS-CoV-2 screening has been capable of revealing the spread of the disease in Europe [3] . After our first successful attempt at using rapid immunochromatographic testing (RICT) to screen for SARS-CoV-2 antibodies in Castiglione d'Adda, an area of early viral circulation in Northern Italy [4] , we not only extended the programme to five other towns in Lombardy, but also included rapid HCV screening in three: San Pellegrino Terme (4,840 inhabitants) and Suisio (3, Cincinnati, OH, USA). They also completed a questionnaire to ascertain whether they were aware of a previous HCV infection.

A total of 5,152 subjects (42.6% of the inhabitants of the three towns together) underwent SARS-CoV-2 screening, and almost half of these (n=2,505, 48.6%) also underwent HCV screening, including 79.3% of those aged >50 years. Table 1 On the basis of historical data, the overall seroprevalence of HCV in Italy is about 2% (1.6-7.3%), with the vast majority of infections reported in subjects aged >60 years, and an increasing gradient from northern to southern Italy [5] . The 2.9% seroprevalence observed in our study is similar to the northern Italian general population estimates made about 20 years ago (3.3%) [6] .

The fact that 53.9% of the HCV-positive subjects were unaware of their serostatus may seem high but it is lower than the estimated 66% made by a European study in 2015 [7] . 

SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening

Global epidemiology and genotype distribution of the hepatitis C virus infection

Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy